Introduction: The incidence of cephalic arch (CA) and central venous (CV) stenosis has been reported in the range of 30% in the literature. The purpose of this study is to compare contrast use, fluoroscopy time, and procedure time between standard imaging by injection of contrast through the access sheath versus injection of contrast through a novel PTA balloon with an integrated injection port.
Methods: A multi-centered, retrospective evaluation of consecutive patients treated for CA and CV stenosis was performed. Data captured included demographics, co-morbidities, lesion characteristics/location, procedural details, volume of contrast used, fluoroscopy time, and procedure time. The control group was imaged and treated using standard practice with pre and post imaging performed through the sheath and intervention using standard PTA balloon. Imaging and treatment were performed using the Chameleon™ PTA catheter in the treatment arm.
Results: A total of 68 consecutive patients were included. There were 34 patients in Group A and 34 patients in Group B. Average age was 65.2 versus 66.5 ( = 0.284), respectively. There were no significant gender differences between groups. Prevalence of co-morbidities of hypertension, coronary artery disease, and diabetes was similar to national rates in both groups. Contrast volume, fluoroscopy time, and procedure time in Group B were significantly less when compared by multiple regression to Group A, correcting for potential confounders ( = 0.0001, 0.0180, and 0.0008, respectively).
Conclusion: Use of a PTA balloon with an integrated injection port shows potential for significant reduction in contrast dose, fluoroscopy time, and procedure time.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1129729820979479 | DOI Listing |
J Vasc Interv Radiol
December 2024
Vascular and Interventional Radiology Translational Research Lab, Mayo Clinic, Rochester, MN, USA; Department of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address:
J Endovasc Ther
December 2024
Department of Vascular Surgery, First Medical Center of PLA General Hospital, Beijing, China.
Purpose: Previous studies have indicated mixed short-term outcomes between drug-coated balloon (DCB) angioplasty and percutaneous transluminal angioplasty (PTA) in the treatment of infrapopliteal lesions. However, the long-term durability of DCB angioplasty remains uncertain. The objective of this study is to present the long-term outcomes of DCB angioplasty for infrapopliteal lesions in patients with critical limb ischemia (CLI).
View Article and Find Full Text PDFVascular
December 2024
Universidad Nacional Autónoma de Mexico, Mexico City, Mexico.
Background: Endovascular therapy with balloon percutaneous angioplasty (PTA) in the femoro-popliteal segment is frequently performed, however, long-term favorable outcomes and patency remain challenging, with restenosis rates reaching 60% post-standard balloon angioplasty. Drug-coated balloons (DCBs) have shown promise in improving these outcomes; Paclitaxel, used in DCBs, inhibits hyperplasia and smooth muscle cell proliferation, reducing restenosis; however, the optimal dose of Paclitaxel remains unclear, with high-dose (HD-DCB [>3 mg/mm]) and low-dose (LD-DCB [<2.0 mg/mm]) options available.
View Article and Find Full Text PDFIndian J Nephrol
June 2024
Department of Nephrology, Meenakshi Mission Hospital Research Centre, Madurai, Tamil Nadu, India.
Background: This study aims to evaluate the technical and clinical outcomes of endovascular treatment for failed native hemodialysis fistulas, mainly the role of balloon angioplasty in salvaging thrombosed and stenosed arteriovenous fistulas.
Materials And Methods: This retrospective study was done on 23 patients who had presented with non-functioning dialysis fistulas. The mean age of the patients was 58.
J Hypertens
January 2025
Department of Photomedicine and Physical Chemistry, Medical College of The Rzeszów University, Rzeszów, Poland.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!